(177)Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience

To compare the efficacy and safety of (177)Lu-DOTATATE plus radiosensitizing capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). MATERIALS AND METHODS: Data of consecutive patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Satapathy, Swayamjeet, Mittal, Bhagwant R., Sood, Ashwani, Sood, Apurva, Kapoor, Rakesh, Gupta, Rajesh, Khosla, Divya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457785/
https://www.ncbi.nlm.nih.gov/pubmed/34288699
http://dx.doi.org/10.1200/GO.21.00103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457785/
https://www.ncbi.nlm.nih.gov/pubmed/34288699
http://dx.doi.org/10.1200/GO.21.00103

Ejemplares similares